TY - JOUR
T1 - TBK1 is a synthetic lethal target in cancer with VHL loss
AU - Hu, Lianxin
AU - Xie, Haibiao
AU - Liu, Xijuan
AU - Potjewyd, Frances
AU - James, Lindsey I.
AU - Wilkerson, Emily M.
AU - Herring, Laura E.
AU - Xie, Ling
AU - Chen, Xian
AU - Cabrera, Johnny Castillo
AU - Hong, Kai
AU - Liao, Chengheng
AU - Tan, Xianming
AU - Baldwin, Albert S.
AU - Gong, Kan
AU - Zhang, Qing
N1 - Funding Information:
We thank the UNC LCCC Tissue Procurement Facility, UNC Animal Studies Core, and UNC Translational Pathology Laboratory for excellent help. We thank Prof. Dr. Michael Kracht, Dr. Samuel Bakhoum, and Dr. Xuewu Zhang for providing FLAG-TBK1, shSTING plasmids, and TBK1 structure information, respectively. We would like to thank the Kidney Cancer Research Program (KCRP) at UT Southwestern for providing us materials with testing. This work was supported in part by a Department of Defense Kidney Cancer Research Program Idea Development Award (W81XWH1910813, to Q. Zhang), Kidney Cancer Research Alliance (KCCure), Cancer Prevention and Research Institute of Texas (CPRIT; RP190058, to Q. Zhang), and the National Cancer Institute (R01CA211732 and R21CA223675, Q. Zhang; R35CA197684, to A.S. Baldwin). Q. Zhang is an American Cancer Society Research Scholar, V Scholar, Kimmel Scholar, Susan G. Komen Career Catalyst awardee, and Mary Kay Foundation awardee. This research is based in part upon work conducted using the UNC Proteomics Core Facility, which is supported in part by the P30 CA016086 Cancer Center Core Support Grant to the UNC Lineberger Comprehensive Cancer Center.
Funding Information:
We thank the UNC LCCC Tissue Procurement Facility, UNC Animal Studies Core, and UNC Translational Pathology Laboratory for excellent help. We thank Prof. Dr. Michael Kracht, Dr. Samuel Bak-houm, and Dr. Xuewu Zhang for providing FLAG-TBK1, shSTING plasmids, and TBK1 structure information, respectively. We would like to thank the Kidney Cancer Research Program (KCRP) at UT Southwestern for providing us materials with testing. This work was supported in part by a Department of Defense Kidney Cancer Research Program Idea Development Award (W81XWH1910813, to Q. Zhang), Kidney Cancer Research Alliance (KCCure), Cancer Prevention and Research Institute of Texas (CPRIT; RP190058, to Q. Zhang), and the National Cancer Institute (R01CA211732 and R21CA223675, Q. Zhang; R35CA197684, to A.S. Baldwin). Q. Zhang is an American Cancer Society Research Scholar, V Scholar, Kimmel Scholar, Susan G. Komen Career Catalyst awardee, and Mary Kay Foundation awardee. This research is based in part upon work conducted using the UNC Proteomics Core Facility, which is supported in part by the P30 CA016086 Cancer Center Core Support Grant to the UNC Lineberger Comprehensive Cancer Center.
Publisher Copyright:
© 2019 American Association for Cancer Research.
PY - 2020/3
Y1 - 2020/3
N2 - TANK binding kinase 1 (TBK1) is an important kinase involved in the innate immune response. Here we discover that TBK1 is hyperactivated by von Hippel-Lindau (VHL) loss or hypoxia in cancer cells. Tumors from patients with kidney cancer with VHL loss display elevated TBK1 phosphorylation. Loss of TBK1 via genetic ablation, pharmacologic inhibition, or a new cereblonbased proteolysis targeting chimera specifically inhibits VHL-deficient kidney cancer cell growth, while leaving VHL wild-type cells intact. TBK1 depletion also significantly blunts kidney tumorigenesis in an orthotopic xenograft model in vivo. Mechanistically, TBK1 hydroxylation on Proline 48 triggers VHL as well as the phosphatase PPM1B binding that leads to decreased TBK1 phosphorylation. We identify that TBK1 phosphorylates p62/SQSTM1 on Ser366, which is essential for p62 stability and kidney cancer cell proliferation. Our results establish that TBK1, distinct from its role in innate immune signaling, is a synthetic lethal target in cancer with VHL loss. SIGNIFICANCE: The mechanisms that lead to TBK1 activation in cancer and whether this activation is connected to its role in innate immunity remain unclear. Here, we discover that TBK1, distinct from its role in innate immunity, is activated by VHL loss or hypoxia in cancer.
AB - TANK binding kinase 1 (TBK1) is an important kinase involved in the innate immune response. Here we discover that TBK1 is hyperactivated by von Hippel-Lindau (VHL) loss or hypoxia in cancer cells. Tumors from patients with kidney cancer with VHL loss display elevated TBK1 phosphorylation. Loss of TBK1 via genetic ablation, pharmacologic inhibition, or a new cereblonbased proteolysis targeting chimera specifically inhibits VHL-deficient kidney cancer cell growth, while leaving VHL wild-type cells intact. TBK1 depletion also significantly blunts kidney tumorigenesis in an orthotopic xenograft model in vivo. Mechanistically, TBK1 hydroxylation on Proline 48 triggers VHL as well as the phosphatase PPM1B binding that leads to decreased TBK1 phosphorylation. We identify that TBK1 phosphorylates p62/SQSTM1 on Ser366, which is essential for p62 stability and kidney cancer cell proliferation. Our results establish that TBK1, distinct from its role in innate immune signaling, is a synthetic lethal target in cancer with VHL loss. SIGNIFICANCE: The mechanisms that lead to TBK1 activation in cancer and whether this activation is connected to its role in innate immunity remain unclear. Here, we discover that TBK1, distinct from its role in innate immunity, is activated by VHL loss or hypoxia in cancer.
UR - http://www.scopus.com/inward/record.url?scp=85081085552&partnerID=8YFLogxK
U2 - 10.1158/2159-8290.CD-19-0837
DO - 10.1158/2159-8290.CD-19-0837
M3 - Article
C2 - 31810986
AN - SCOPUS:85081085552
VL - 10
SP - 460
EP - 475
JO - Cancer Discovery
JF - Cancer Discovery
SN - 2159-8274
IS - 3
ER -